FPA008
Phase 1Biologic
FPA008 is one of 42 biologic programs targeting Giant Cell Tumor. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Orencia
Bristol-Myers SquibbPreclinical
Actemra
RochePreclinical
Cimzia
UCBPreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Actos
TakedaPreclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Certolizumab
Johnson & JohnsonPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FPA008. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- FFive Prime Therapeutics, Inc.